The mRNA level of Charcot–Leyden crystal protein/galectin-10 is a marker for CRTH2 activation in human whole blood in vitro

Author: Lin Tai-An   Kourteva Galina   Hilton Holly   Li Hongli   Tare Nadine S.   Carvajal Valerie   Hang Julie S.   Wei Xin   Renzetti Louis M.  

Publisher: Informa Healthcare

ISSN: 1366-5804

Source: Biomarkers, Vol.15, Iss.7, 2010-11, pp. : 646-654

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

CRTH2 is one of the prostaglandin D2 receptors and plays a proinflammatory role in allergic diseases. Gene expression markers in whole blood induced by CRTH2 activation have not previously been reported. Using microarray analyses of 54 675 genes, we revealed modest gene expression changes in human whole blood stimulated in vitro by a selective CRTH2 agonist, DK-PGD2. Five genes were found to exhibit 1.5- to 2.6-fold changes in expression. The expression of Charcot–Leyden crystal protein/galectin-10 (CLC/Gal-10) in particular was consistently enhanced in human whole blood stimulated by DK-PGD2, as confirmed by quantitative real-time polymerase chain reaction analyses. DK-PGD2-induced increases in blood CLC/Gal-10 mRNA levels were largely attenuated by the CRTH2 antagonist CAY10471.Thus, the DK-PGD2-induced CLC/Gal-10 mRNA level can serve as a potential marker for monitoring pharmacodynamic effects of blood exposure to CRTH2 modulating agents.

Related content